Myrbetriq Oral Tablet, Extended Release 25Mg Drug Medication Dosage Information
show timeout overlay link

Your Session Is About to Expire

This online session is about to expire due to inactivity. Click Continue to return to page.

  • Weekly Ad

Myrbetriq: Oral tablet, extended release (25mg)

Also see:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics

Visit Drug Summary Page
Drug Image file DrugItem_16517.JPG
Myrbetriq 25mg ER Tablet
Astellas Pharma US, Inc.
Pill Identification: LOGO 325 

What is this Medicine?

MIRABEGRON (MIR a BEG ron) is used to treat overactive bladder. This medicine reduces the amount of bathroom visits. It may also help to control wetting accidents.

CVS Pharmacy Patient Statistics for Myrbetriq: Oral tablet, extended release(25mg)
Generic vs. Brand Name Usage*
*Brand contains same active ingredient but may not represent FDA-approved generic equivalent
Usage By Strength
In-Depth Information

Myrbetriq 25mg Extended-Release Tablet

NDC: 004692601
  • Prescription Required
  • Not a Controlled Drug
    (CSA Schedule)
  • FDA Approved




FDA approved for the following conditions:
Urinary Incontinence, Overactive Bladder (OAB)

Storage Information
Store at 77 degrees F; excursions permitted to 59-86 degrees F
Myrbetriq 25mg Extended-Release Tablet
Drug Image file DrugItem_16517.JPG
Astellas Pharma US, Inc.
Pill Identification: LOGO 325 
Shape: oval
Color: brown

Reported Side Effects for Myrbetriq 25mg Extended-Release Tablet

Bladder Discomfort Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Vaginal Irritation Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Rhinitis Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Skin Rash Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Bruises Incidence:
<1.0%*
Severity: MILD
Onset: DELAYED
Rapid Heart Rate Incidence:
<1.0%*
Severity: MODERATE
Onset: EARLY
Inflamed Blood Vessels Incidence:
<1.0%*
Severity: SEVERE
Onset: DELAYED
Hives Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Upset Stomach Incidence:
<1.0%*
Severity: MILD
Onset: EARLY
Swelling Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Inflamed Stomach Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Sinus Infection Incidence:
<2.7%*
Severity: MILD
Onset: DELAYED
Itching Incidence:
<1.0%*
Severity: MILD
Onset: RAPID
Kidney Stones Incidence:
<1.0%*
Severity: MODERATE
Onset: DELAYED
Irregular Heart Beat Incidence:
0.2%*
Severity: SEVERE
Onset: EARLY
Brain Attack Incidence:
0.4%*
Severity: SEVERE
Onset: EARLY
Stomach Pain Incidence:
0.6-1.4%*
Severity: MILD
Onset: EARLY
Tired Incidence:
1.2-1.4%*
Severity: MILD
Onset: EARLY
Loose Stools Incidence:
1.2-1.5%*
Severity: MILD
Onset: EARLY
Rapid Heart Rate Incidence:
1.2-1.6%*
Severity: MODERATE
Onset: RAPID
Joint Pain Incidence:
1.3-2.1%*
Severity: MILD
Onset: DELAYED
Constipation Incidence:
1.6-2.8%*
Severity: MODERATE
Onset: DELAYED
Headache Incidence:
2.1-4.1%*
Severity: MILD
Onset: EARLY
Bladder Infection Incidence:
2.1%*
Severity: MODERATE
Onset: DELAYED
Flu Incidence:
2.6%*
Severity: MILD
Onset: DELAYED
Lightheadedness Incidence:
2.7%*
Severity: MILD
Onset: EARLY
Back Pain Incidence:
2.8%*
Severity: MILD
Onset: DELAYED
Dry Mouth Incidence:
2.8%*
Severity: MILD
Onset: EARLY
Sore Throat Incidence:
3.5-3.9%*
Severity: MILD
Onset: DELAYED
High Blood Pressure Incidence:
7.5-11.3%*
Severity: MODERATE
Onset: EARLY
*This is an approximate aggregated range of reported side effects from clinical studies performed on this drug. Your experience with this drug may be different.
Pregnancy & Lactation Information
FIRST Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

SECOND Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

THIRD Trimester

Class C - Animal studies have shown an adverse effect and there are no adequate and well-controlled studies in pregnant women. OR No animal studies have been conducted and there are no adequate and well-controlled studies in pregnant women.

Lactation

Caution - Not enough information is available to rule out harm to infants when this drug is taken by nursing mothers.


Learning More About
Visit the Drug Summary page where you can:
  • Get answers to Frequently Asked Questions (FAQs)
  • Find other class related drugs
  • Find additional patient usage statistics
Learn More
Patient Experiences with Myrbetriq

We want to help you stay educated about the medications you are taking. View other
patient's observations and share your own.

Be sure to consult your health care provider before taking any medications. Other
patient's comments should not be considered medical advice or health care provider
recommendations.